Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Kiadis Pharma N.V.    KDS   NL0011323407

KIADIS PHARMA N.V.

(KDS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Amsterdam
01/15/2021 01/18/2021 01/19/2021 01/20/2021 01/21/2021 Date
5.26(c) 5.27(c) 5.3(c) 5.29(c) 5.325(c) Last
308 298 82 220 226 592 62 519 200 232 Volume
-0.28% +0.19% +0.57% -0.19% +0.66% Change
More quotes
Financials
Sales 2020 8,80 M 10,7 M 10,7 M
Net income 2020 -31,7 M -38,6 M -38,6 M
Net Debt 2020 - - -
P/E ratio 2020 -6,10x
Yield 2020 -
Sales 2021 10,1 M 12,3 M 12,3 M
Net income 2021 -36,7 M -44,6 M -44,6 M
Net Debt 2021 - - -
P/E ratio 2021 -5,98x
Yield 2021 -
Capitalization 215 M 261 M 261 M
Capi. / Sales 2020 24,4x
Capi. / Sales 2021 21,3x
Nbr of Employees 170
Free-Float 98,0%
More Financials
Company
Kiadis Pharma N.V., is a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with life-threatening diseases. With headquarters in Amsterdam, the Netherlands, and offices in the US and across Europe, Kiadis Pharma N.V. is leveraging the natural strengths of humanity and our collective immune system to source the best cells for life. 
More about the company
Notations Surperformance© of Kiadis Pharma N.V.
Trading Rating : Investor Rating : -
More Ratings
All news about KIADIS PHARMA N.V.
01/15KIADIS PHARMA N : draws EUR20 million from bridge loan with Sanofi
AQ
01/14KIADIS PHARMA N : Takes $24.2 Million From Bridge Loan With Sanofi
MT
01/11Sanofi buys Kymab for up to $1.5 billion to expand in immunotherapy
RE
2020KIADIS PHARMA N.V. : Crossing thresholds
CO
2020KIADIS PHARMA N.V. : Crossing thresholds
CO
2020Sanofi's $374 Million Kiadis Takeover Clears Competition Hurdle
MT
2020KIADIS PHARMA N.V. : Admission of new securities
CO
2020KIADIS PHARMA N : to present at the Piper Sandler 32nd Annual Virtual Healthcare..
PU
2020KIADIS PHARMA N : to present at the Piper Sandler 32nd Annual Virtual Healthcare..
AQ
2020KIADIS PHARMA N : to present at the Piper Sandler 32nd Annual Virtual Healthcare..
AQ
2020KIADIS PHARMA N.V. : Crossing thresholds
CO
2020KIADIS PHARMA N : issues options to newly hired employees to meet its existing o..
PU
2020KIADIS PHARMA N : issues options to newly hired employees to meet its existing o..
AQ
2020KIADIS PHARMA N : issues options to newly hired employees to meet its existing o..
AQ
2020KIADIS PHARMA N : announces presentations at the 2020 ASH Annual Meeting and Exp..
AQ
More news
News in other languages on KIADIS PHARMA N.V.
2020Le soleil se lève à l'Est
2020EN DIRECT DES MARCHES : Axa, Sanofi, Accor, Nexans, Altice Europe, Siltronic, Te..
2020SANOFI : prévoit de finaliser le rachat de Kiadis au S1 2021
2020WALL STREET STOCK EXCHANGE : Rebond en vue à Wall Street à J-1 de la présidentie..
2020Les Bourses européennes dans le vert grâce aux PMI
More news
Chart KIADIS PHARMA N.V.
Duration : Period :
Kiadis Pharma N.V. Technical Analysis Chart | KDS | NL0011323407 | MarketScreener
Technical analysis trends KIADIS PHARMA N.V.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 5,36 €
Last Close Price 5,33 €
Spread / Highest target 2,35%
Spread / Average Target 0,66%
Spread / Lowest Target -6,10%
EPS Revisions
Managers and Directors
NameTitle
Arthur K. Lahr Chief Executive Officer
Mark A. Wegter Chairman-Supervisory Board
Dirk de Naeyer Chief Operating Officer
Paul van Hagen Senior Vice President-Finance
Andrew S. Sandler Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
KIADIS PHARMA N.V.0.95%261
MODERNA, INC.27.29%49 519
LONZA GROUP AG4.32%49 499
CELLTRION, INC.-13.09%38 562
IQVIA HOLDINGS INC.4.76%36 531
SEAGEN INC.6.08%34 515